ARCHEMIX ANNOUNCES STRATEGIC ALLIANCE WITH ELAN TO DISCOVER AND DEVELOP APTAMER THERAPEUTICS
Archemix Corp. announced today a multi-year, multi-product alliance with Elan Corporation, plc focused on the discovery, development, and commercialization of first-in-class aptamer therapeutics to treat autoimmune disease. The companies will seek to develop
aptamer therapeutics to IL-23, a cytokine that has emerged as a mediator in the
chronic autoimmune inflammatory diseases, and additional protein targets.